Cleared Traditional

K831207 - SPUNGUARD SCRUB SUIT

K831207 is an FDA 510(k) clearance for SPUNGUARD SCRUB SUIT, manufactured by Kimberly-Clark Corp.. The device is a Class 1 General Hospital device with product code FXO cleared through the Traditional 510(k) pathway after a 34-day FDA review.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
May 1983
Decision
34d
Days
Class 1
Risk

K831207 is an FDA 510(k) clearance for the SPUNGUARD SCRUB SUIT. Classified as Suit, Surgical (product code FXO), Class I - General Controls.

Submitted by Kimberly-Clark Corp. (Mchenry, US). The FDA issued a Cleared decision on May 16, 1983 after a review of 34 days - a notably fast clearance cycle.

This device falls under the General Hospital FDA review panel, regulated under 21 CFR 878.4040 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Kimberly-Clark Corp. devices

FDA 510(k) Submission Details - K831207

510(k) Number K831207 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 12, 1983
Decision Date May 16, 1983
Days to Decision 34 days
Submission Type Traditional
Review Panel General Hospital (HO)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
95d faster than avg
Panel avg: 129d · This submission: 34d
Pathway characteristics
Predicate-based equivalence.

FXO Device Classification - Class 1, General Controls

Product Code FXO Suit, Surgical
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 878.4040
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.